ELEV
Price:
$0.6
Market Cap:
$35.47M
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.[Read more]
Industry
Biotechnology
IPO Date
2021-06-25
Stock Exchange
NASDAQ
Ticker
ELEV
According to Elevation Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is -59.73%. This represents a change of 298.00% compared to the average of -15.01% of the last 4 quarters.
The mean historical ROE of Elevation Oncology, Inc. over the last ten years is -25.02%. The current -59.73% ROE has changed 138.71% with respect to the historical average. Over the past ten years (40 quarters), ELEV's ROE was at its highest in in the December 2020 quarter at 38.52%. The ROE was at its lowest in in the March 2020 quarter at -148.67%.
Average
-25.02%
Median
-22.77%
Minimum
-193.91%
Maximum
100.15%
Discovering the peaks and valleys of Elevation Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 751.56%
Maximum Annual ROE = 100.15%
Minimum Annual Increase = -130.44%
Minimum Annual ROE = -193.91%
Year | ROE | Change |
---|---|---|
2023 | -83.39% | -57.00% |
2022 | -193.91% | 751.56% |
2021 | -22.77% | -130.44% |
2020 | 74.80% | -25.31% |
The current ROE of Elevation Oncology, Inc. (ELEV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-100.02%
5-year avg
-25.02%
10-year avg
-25.02%
Elevation Oncology, Inc.’s ROE is less than CohBar, Inc. (0%), greater than Ocean Biomedical, Inc. (-58.44%), less than AVROBIO, Inc. (75.64%), less than Zura Bio Limited (29.68%), greater than Enveric Biosciences, Inc. (-39.61%), greater than Hepion Pharmaceuticals, Inc. (-201.01%), greater than null (-505.74%),
Company | ROE | Market cap |
---|---|---|
0% | $1.28M | |
-58.44% | $24.17M | |
75.64% | $5.24M | |
29.68% | $188.05M | |
-39.61% | $3.33M | |
-201.01% | $4.31M | |
-505.74% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Elevation Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Elevation Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Elevation Oncology, Inc.'s ROE?
How is the ROE calculated for Elevation Oncology, Inc. (ELEV)?
What is the highest ROE for Elevation Oncology, Inc. (ELEV)?
What is the 3-year average ROE for Elevation Oncology, Inc. (ELEV)?
What is the 5-year average ROE for Elevation Oncology, Inc. (ELEV)?
How does the current ROE for Elevation Oncology, Inc. (ELEV) compare to its historical average?